Improving CAR T cell therapy for brain tumors using immune competent models

使用免疫活性模型改善脑肿瘤的 CAR T 细胞疗法

基本信息

  • 批准号:
    10732795
  • 负责人:
  • 金额:
    $ 24.9万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-01-01 至 2025-12-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY/ABSTRACT The overall objective of this study is to engineer a potent CAR T cell therapy for high grade glioma (HGG), a subgroup of brain tumors for which outcomes remain poor. CAR T cell therapy is an innovative technology based on adoptive transfer of antigen-specific T cells engineered to elicit a clinically effective and specific immune response against tumor cells. Early clinical studies in HGG patients demonstrated safety of CAR T cell therapy for brain tumors; yet, only limited benefits were observed. Lack of efficacy is most likely multifactorial and include heterogenous antigen expression, limited homing to and penetration of tumors, T cell exhaustion and limited persistence, as well as the immunosuppressive tumor microenvironment (TME). Therefore, the central hypothesis of this proposal is that optimized design and additional genetic modifications of CAR T cells will improve their antitumor effects, and that these interventions will be evaluated in immune competent mouse models that closely mimic human disease. Three interrelated research aims are proposed to test this hypothesis and the rationale of each is outlined below. First, CAR design has to be optimized and evaluated in immune competent glioma models. In Aim 1, I will generate CAR T cells containing different co- stimulatory domains (CD28.ζ, 41BB.ζ, CD28.mutζ, and 41BB.mutζ), and compare their activity in vitro and in vivo. Second, a genome wide screen in primary T cells has identified key regulators of T cell activation post T- cell receptor (TCR) stimulation. Identified genes belong to molecules that regulate cell cycle, proliferation, and downstream TCR signaling including SOCS1, RASA2, or CBLB. In Aim 2, I will therefore explore if CRISPR- Cas9 mediated silencing of Socs1, Rasa2, and/or Cblb enhances the effector functions of CAR T cells. The independent Aim 3 will then explore a dual CAR targeting approach in which I will not only target glioma cells but also immunosuppressive cells within the glioma microenvironment. These studies are focused on tumor associated macrophages (TAMs), since they are abundantly present in gliomas and play a critical role in shaping the TME. To support the feasibility of this project, I have adapted the well-established immune competent GL261 glioma model to study CAR T cell therapies targeting the relevant tumor antigen B7-H3, which is not only expressed by GL261 cells but also in a broad range of pediatric and adult brain tumors. In addition, my preliminary studies indicate that `prototype' B7- H3 CAR T-cells readily recognize and kill GL261 cells in vitro and have antitumor activity in vivo, highlighting that the developed model is well suited for the proposed aims of this project. State of the art technique will be used in all three Aims to not only study the function and in vivo fate of CAR T-cells, but also their antitumor activity, and how CAR T-cells interact with glioma- infiltrating immune cells. Completion of this study will define the most optimal CAR design that best controls HGG tumors and persists longer in the context of inflammatory brain tumors. Additionally, results will illustrate if targeting TAMs will overcome the suppressive effects of TME on B7-H3 CAR T cells.
项目摘要/摘要 这项研究的总体目标是设计一种有效的CAR T细胞治疗高级别胶质瘤(HGG), 结果仍然很差的脑肿瘤的一个亚群。汽车T细胞疗法是一项创新技术 基于过继转移抗原特异性T细胞的基因工程诱导临床有效和特异 针对肿瘤细胞的免疫反应。HGG患者的早期临床研究证明CAR T细胞是安全的 脑瘤的治疗;然而,只观察到有限的好处。疗效的缺乏很可能是多因素的 包括异质性抗原表达,肿瘤的有限归巢和穿透,T细胞耗竭 和有限的持久性,以及免疫抑制肿瘤微环境(TME)。因此, 这一提议的中心假设是,汽车的优化设计和额外的遗传修改 T细胞将提高其抗肿瘤效果,这些干预措施将在免疫学中进行评估 近乎模拟人类疾病的合格小鼠模型。提出了三个相互关联的研究目标 下面概述了检验这一假说和每种假说的基本原理。首先,必须优化汽车设计,并 在免疫活性胶质瘤模型中进行评估。在目标1中,我将生成包含不同co-1的CAR T细胞 刺激结构域(CD28.ζ、41Bb.ζ、CD28.mutζ和41BB.mutζ),并比较它们在体外和体内的活性 活着。其次,在初级T细胞中的全基因组筛查已经确定了T细胞在T细胞死亡后激活的关键调节因子。 细胞受体(TCR)刺激。已识别的基因属于调节细胞周期、增殖和 下行TCR信令包括SOCS1、RASA2或CBLB。因此,在目标2中,我将探讨CRISPR是否- Cas9介导的Socs1、Rasa2和/或Cblb沉默增强了CAR T细胞的效应功能。这个 然后,《独立目标3》将探索一种双重CAR靶向方法,在这种方法中,我不仅将靶向胶质瘤细胞 还包括胶质瘤微环境中的免疫抑制细胞。这些研究都集中在肿瘤上。 相关巨噬细胞(TAM),因为它们在胶质瘤中大量存在,并在形成过程中发挥关键作用 TME。为了支持这个项目的可行性,我对成熟的免疫功能GL261进行了改造 胶质瘤模型研究针对相关肿瘤抗原B7-H3的CAR T细胞治疗,这不仅是 不仅在GL261细胞中表达,而且在儿童和成人脑肿瘤中也有表达。此外,我的 初步研究表明“原型”B7-H3CAR T细胞在体外很容易识别和杀伤GL261细胞 并在体内具有抗肿瘤活性,突出表明所开发的模型非常适合所提出的目标 这个项目。最先进的技术将用于所有这三个目标,不仅是为了研究功能和体内命运 CAR T细胞及其抗肿瘤活性,以及CAR T细胞如何与胶质瘤浸润性免疫相互作用 细胞。这项研究的完成将确定最优的汽车设计,最好地控制HGG肿瘤和 在炎症性脑瘤的情况下持续时间更长。此外,结果将说明是否以TAMs为目标 将克服TME对B7-H3CAR T细胞的抑制作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Dalia Haydar其他文献

Dalia Haydar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Dalia Haydar', 18)}}的其他基金

Improving CAR T cell therapy for brain tumors using immune competent models
使用免疫活性模型改善脑肿瘤的 CAR T 细胞疗法
  • 批准号:
    10322192
  • 财政年份:
    2021
  • 资助金额:
    $ 24.9万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.9万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 24.9万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 24.9万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 24.9万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 24.9万
  • 项目类别:
    Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 24.9万
  • 项目类别:
    Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
  • 批准号:
    2230829
  • 财政年份:
    2023
  • 资助金额:
    $ 24.9万
  • 项目类别:
    Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 24.9万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 24.9万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 24.9万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了